COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
Aug 03, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000111.pdf 0001103021-20-000111.rtf 0001103021-20-000111.xls
Jul 24, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000104.pdf 0001103021-20-000104.rtf 0001103021-20-000104.xls
Jul 15, 2020	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000101.pdf 0001103021-20-000101.rtf 0001103021-20-000101.xls
Jun 17, 2020	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000098.pdf 0001103021-20-000098.rtf 0001103021-20-000098.xls
Jun 01, 2020	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000095.pdf 0001103021-20-000095.rtf 0001103021-20-000095.xls
May 22, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000090.pdf 0001103021-20-000090.rtf 0001103021-20-000090.xls
May 22, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000092.pdf 0001103021-20-000092.rtf 0001103021-20-000092.xls
May 20, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000087.pdf 0001103021-20-000087.rtf 0001103021-20-000087.xls
May 14, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000085.pdf 0001103021-20-000085.rtf 0001103021-20-000085.xls
May 12, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000079.pdf 0001103021-20-000079.rtf 0001103021-20-000079.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results March 10, 2021

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today ...

BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021 February 17, 2021

RALEIGH, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full ...

BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President February 11, 2021

Brings Track Record of Success to Expanded Role RALEIGH, N.C. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now